CarnoSyn® Brands Launches CarnoSyn® 4X, a Next-Generation Beta-Alanine for Sports Performance

Key Terms

beta-alanine medical

A naturally occurring amino acid used primarily as an ingredient in sports and dietary supplements to raise muscle levels of carnosine, which can help delay fatigue during short bursts of intense exercise. Investors monitor beta-alanine because its scientific support, regulatory status, supply chain, and consumer trends directly affect sales and profitability of supplement makers and food companies—think of it as a popular recipe ingredient that can drive product demand or regulatory scrutiny.

paresthesia medical

Paresthesia is an abnormal skin sensation such as tingling, numbness, burning or “pins and needles,” often described like a hand or foot that has temporarily “fallen asleep.” In financial and clinical reporting, mention of paresthesia flags a potential safety or tolerability issue with a drug or device that can influence regulatory review, prescribing decisions and investor confidence—similar to a dashboard warning that prompts closer scrutiny.

bioavailability medical

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

new dietary ingredient (ndi) status regulatory

New dietary ingredient (NDI) status is a regulatory label for a dietary supplement component that was not sold in the U.S. in a dietary supplement before a set cutoff date, meaning manufacturers generally must notify the Food and Drug Administration and provide safety information before marketing. For investors, NDI status signals regulatory review risk—like needing a permit before building an addition—so approval uncertainty, potential delays, or safety questions can affect a product’s revenue prospects and a company’s legal exposure.

restricted stock financial

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

omnibus incentive plan financial

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

New proprietary formulation delivers more than four times the bioavailability of standard beta-alanine without paresthesia.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Natural Alternatives International, Inc. (NAI) is launching CarnoSyn® 4X, the most advanced CarnoSyn® beta-alanine formulation to date. The ingredient delivers more than four times the bioavailability of standard beta-alanine without paresthesia, the tingling sensation often associated with beta-alanine usage.

For decades, CarnoSyn® has helped everyday and elite athletes train harder and recover faster. CarnoSyn® 4X quadruples bioavailability in a proprietary formula for efficacious dosing without paresthesia.

The proprietary, patent-pending ingredient gives sports nutrition brands a new way to deliver trusted CarnoSyn® beta-alanine benefits to a wider audience with greater efficiency, improved user experience, and lower cost-in-use potential.

“The CarnoSyn® brand name has stood for trusted performance in sports nutrition for more than 20 years, and CarnoSyn® 4X represents the next evolution of that legacy,” said Kenneth Wolf, President and Chief Operating Officer of NAI. “CarnoSyn® 4X gives formulators a way to expand the beta-alanine audience, reaching consumers who may have avoided it because of the tingling sensation, while reinforcing the CarnoSyn® name as a trusted on-pack signal of performance.”

Backed by more than 55 clinical studies, the CarnoSyn® portfolio remains the only beta-alanine with New Dietary Ingredient (NDI) status. This innovation gives sports nutrition brands flexibility to pursue line extensions and launch new products featuring beta-alanine across more usage occasions and consumer needs. CarnoSyn® Brands continues to build on its leadership in performance nutrition by delivering clinically supported beta-alanine solutions that meet the evolving needs of brands and consumers alike.

CarnoSyn® 4X is available now. To learn more, visit carnosyn.com/carnosyn-4x.

About CarnoSyn® Brands:

CarnoSyn® Brands feature four clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, CarnoSyn® 4X beta-alanine powder, and TriBsyn™ powder. For more information, visit carnosyn.com and tribsyn.com.

About Natural Alternatives International, Inc. (NAI):

NAI is a leading formulator, manufacturer, and marketer of nutritional supplements and provides strategic partnering services to its customers, including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please visit nai-online.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260420814198/en/

Erin Robbins
MarketPlace
erin.robbins@marketplacebranding.com
1-314-366-3562

Source: Natural Alternatives International, Inc.